期刊
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
卷 414, 期 2, 页码 759-789出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00216-021-03586-z
关键词
Metabolomics; Biomarkers; Personalized medicine; Precision medicine; Point-of-care tests; Immunoassays; Biosensors
资金
- CEA
- European Union [825694]
- MICROB-PREDICT project
Metabolomics involves detecting, quantifying, and analyzing small molecules in biological samples on a large scale. While it has shown relevance for patient stratification in research projects and clinical studies, challenges related to standardization, metabolite identification, and data processing hinder its implementation in clinical practice, especially in personalized medicine. Streamlining complex molecular signatures and improving interoperability of data are crucial for the future integration of metabolomics into healthcare.
Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据